In 2002, large-scale genomic screens allowed uncovering the occurrence of BRAF
mutations in melanomas (67%), colon carcinomas (12%), and ovarian tumors (14%)[1]. In …

The development of targeted therapies creates a need to discriminate tumours accurately by
their histological and genetic characteristics. Here, we aim to identify gene expression …

Background Molecularly targeted therapies improved survival status of some patients with
lung adenocarcinoma, which accounts for 40% of all lung cancers, and in-depth study of …

The development of molecular analyses for thyroid pathologies is on going. These analyses
provide new diagnostic tools with the aim of accurately distinguishing malignant and benign …

BRAFV600E is the most frequent oncogenic mutation identified in papillary thyroid cancer
(PTC). In PTC patients who do not respond to standard treatment, BRAF inhibitors are …

Simple Summary The RAS/RAF/MEK/ERK pathway is implicated in fundamental processes
frequently altered in tumors, such as cell proliferation and survival. In breast cancer, it is …

Incidental thyroid carcinoma (ITC) is defined as a tumor diagnosed at histology after surgical
intervention for a benign thyroid disease and, therefore, without a preoperative diagnosis of …

Mutations in KRAS oncogene are recognized biomarkers that predict lack of response to anti-
epidermal growth factor receptor (EGFR) antibody therapies. However, some patients with …

Background Lung cancer is one of the most incident neoplastic diseases, and a leading
cause of death for cancer worldwide. Knowledge of the incidence of druggable genetic …

Simple Summary BRAF mutations are classified into four categories based on molecular
characteristics, but only Class 1 BRAF V600 have effective targeted treatment strategies …